Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,300 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $114.68, for a total transaction of $607,804.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $116.00, for a total transaction of $2,900,000.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00.
  • On Monday, May 8th, Donald E. Bobo, Jr. sold 19,100 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $110.34, for a total transaction of $2,107,494.00.
  • On Thursday, May 4th, Donald E. Bobo, Jr. sold 34,120 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $109.98, for a total transaction of $3,752,517.60.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down 0.41% on Friday, reaching $113.11. 1,134,626 shares of the company’s stock traded hands. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market capitalization of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. The firm’s 50 day moving average is $116.42 and its 200 day moving average is $106.02.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. During the same period in the prior year, the firm earned $0.76 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,300 Shares” was originally posted by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://rinconhillneighbors.org/2017/08/19/donald-e-bobo-jr-sells-5300-shares-of-edwards-lifesciences-corporation-nyseew-stock-updated-updated.html.

A number of equities research analysts recently issued reports on EW shares. Vetr raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $116.04 price target on the stock in a research note on Thursday, May 4th. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a research note on Tuesday, July 18th. Finally, Cowen and Company reissued an “outperform” rating and issued a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $121.13.

Several large investors have recently bought and sold shares of EW. Vanguard Group Inc. increased its stake in Edwards Lifesciences Corporation by 2.0% in the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after buying an additional 406,901 shares during the last quarter. BlackRock Inc. increased its stake in Edwards Lifesciences Corporation by 0.8% in the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock valued at $1,668,309,000 after buying an additional 105,819 shares during the last quarter. State Street Corp increased its stake in Edwards Lifesciences Corporation by 1.7% in the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock valued at $883,219,000 after buying an additional 157,844 shares during the last quarter. Alliancebernstein L.P. increased its stake in Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock valued at $539,685,000 after buying an additional 850,168 shares during the last quarter. 84.67% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.